United Therapeutics Corporation (UTHR) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for United Therapeutics Corporation (UTHR).

Download S&P Stocks on Google Play Download S&P Stocks on the App Store

Equity Overview

Price & Market Data

Price: $296.4

Daily Change: +$2.96 / 1.00%

Range: $292.3 - $297.9

Market Cap: $13,312,874,496

Volume: 189,295

Performance Metrics

1 Week: 3.94%

1 Month: -6.41%

3 Months: -20.29%

6 Months: -20.02%

1 Year: 26.64%

YTD: -15.99%

Company Details

Employees: 1305

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Selected stocks

NBT Bancorp Inc. (NBTB)

Hanmi Financial Corporation (HAFC)

Amerisafe, Inc. (AMSF)